[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 470
Citations 0
Comment & Response
March 24/31, 2015

Treatment to Prevent Hepatitis B Virus Reactivation in Patients With Lymphoma Receiving Chemotherapy—Reply

Author Affiliations
  • 1Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
JAMA. 2015;313(12):1270. doi:10.1001/jama.2015.1444

In Reply Dr Baang comments that the HBV reactivation rate of 6.6% with entecavir prophylaxis in our study was relatively higher than the reactivation rate of 1.2% after 5 years of entecavir treatment in patients with chronic HBV in the European Association for the Study of the Liver guidelines.1 We agree that this could be explained by cross-resistance between entecavir and lamivudine. The latter has been extensively used in China, which may cause transmission of lamivudine-resistant viruses in the community.

First Page Preview View Large
First page PDF preview
First page PDF preview
×